A phase I, open label, multi-center, dose escalation study of the safety, tolerability and pharmacokinetic properties of the orally administered negative enantiomer of Gossypol (AT-101) in patients with advanced malignancies

Trial Profile

A phase I, open label, multi-center, dose escalation study of the safety, tolerability and pharmacokinetic properties of the orally administered negative enantiomer of Gossypol (AT-101) in patients with advanced malignancies

Not stated
Phase of Trial: Phase I

Latest Information Update: 30 May 2009

At a glance

  • Drugs AT 101 (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 30 May 2009 Interim pharmacokinetic data presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009).
    • 15 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top